WO2012024581A3 - Composés oxystérol - Google Patents

Composés oxystérol Download PDF

Info

Publication number
WO2012024581A3
WO2012024581A3 PCT/US2011/048414 US2011048414W WO2012024581A3 WO 2012024581 A3 WO2012024581 A3 WO 2012024581A3 US 2011048414 W US2011048414 W US 2011048414W WO 2012024581 A3 WO2012024581 A3 WO 2012024581A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
disclosed
disorders
oxysterol compounds
oxysterol
Prior art date
Application number
PCT/US2011/048414
Other languages
English (en)
Other versions
WO2012024581A2 (fr
Inventor
Matt Epperson
Francine Farouz
Frank Stappenbeck
Wei Xiao
Original Assignee
Fate Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics, Inc. filed Critical Fate Therapeutics, Inc.
Publication of WO2012024581A2 publication Critical patent/WO2012024581A2/fr
Publication of WO2012024581A3 publication Critical patent/WO2012024581A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Abstract

La présente invention concerne des composés destinés à être utilisés dans le traitement de troubles osseux, de l'obésité, de troubles cardiovasculaires et de troubles neurologiques. Les composés ont la structure suivante (I) comprenant les stéréoisomères, les sels pharmaceutiquement acceptables et les promédicaments de ceux-ci, dans laquelle X, Z, E, R1 et q sont tels que définis ici. L'invention concerne également des procédés associés à la préparation et à l'utilisation de tels composés, ainsi que des compositions pharmaceutiques comprenant de tels composés.
PCT/US2011/048414 2010-08-20 2011-08-19 Composés oxystérol WO2012024581A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37554610P 2010-08-20 2010-08-20
US61/375,546 2010-08-20

Publications (2)

Publication Number Publication Date
WO2012024581A2 WO2012024581A2 (fr) 2012-02-23
WO2012024581A3 true WO2012024581A3 (fr) 2012-04-12

Family

ID=44583448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/048414 WO2012024581A2 (fr) 2010-08-20 2011-08-19 Composés oxystérol

Country Status (1)

Country Link
WO (1) WO2012024581A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
EP1993558B1 (fr) 2006-02-27 2014-07-30 The Regents of The University of California Composés oxystérols et hedgehog voie
US9526737B2 (en) 2007-12-03 2016-12-27 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
WO2013169399A1 (fr) * 2012-05-07 2013-11-14 The Regents Of The University Of California Oxy133, un analogue de l'oxystérol, induisant l'ostéo-genèse et la signalisation hedgehog et inhibant l'adipogenèse
US20150140059A1 (en) * 2012-05-07 2015-05-21 The Regents Of The University Of California Novel oxysterol analogue, oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis
WO2014179756A1 (fr) * 2013-05-02 2014-11-06 The Regents Of The University Of California Agents de ciblage osseux à base d'oxystérol ostéogène à sélectivité osseuse
WO2016094421A1 (fr) 2014-12-09 2016-06-16 Warsaw Orthopedic, Inc. Composés et procédés impliquant des stérols
US9877836B2 (en) 2015-07-10 2018-01-30 Warsaw Orthopedic, Inc. Compression resistant implants including an oxysterol and methods of use
US9878070B2 (en) * 2015-06-17 2018-01-30 Warsaw Orthopedic, Inc. Malleable implants including an oxysterol and methods of use
US10632230B2 (en) * 2015-07-10 2020-04-28 Warsaw Orthopedic, Inc. Implants having a high drug load of an oxysterol and methods of use
US9987289B2 (en) 2015-07-10 2018-06-05 Warsaw Orthopedic, Inc. Slow release oxysterols and methods of use
US9987290B2 (en) * 2016-03-28 2018-06-05 Warsaw Orthopedic, Inc. Methods for the separation and detection of an oxysterol
ES2918698T3 (es) * 2016-11-29 2022-07-19 Enanta Pharm Inc Proceso para la preparación de derivados del ácido biliar de las sulfonilureas
US11384114B2 (en) 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
WO2018125746A1 (fr) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. Composés 1h-pyrrole-2,5-dione et leurs procédés d'utilisation pour induire un auto-renouvellement de cellules de support souches/progénitrices
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11464888B2 (en) 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
CN110551166B (zh) * 2018-05-31 2022-06-21 华东师范大学 一种胆酸衍生物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073186A1 (fr) * 2007-12-03 2009-06-11 The Regents Of The University Of California Oxystérols pour l'activation du signal hedgehog, de l'ostéoinduction, de l'anti-adipogenèse et du signal wnt

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073186A1 (fr) * 2007-12-03 2009-06-11 The Regents Of The University Of California Oxystérols pour l'activation du signal hedgehog, de l'ostéoinduction, de l'anti-adipogenèse et du signal wnt

Also Published As

Publication number Publication date
WO2012024581A2 (fr) 2012-02-23

Similar Documents

Publication Publication Date Title
WO2012024584A3 (fr) Composés oxystérol
WO2012024581A3 (fr) Composés oxystérol
WO2012016186A8 (fr) Inhibiteurs de kinases macrocycliques et leurs utilisations
WO2011044501A3 (fr) Analogues d'aminoglycoside antibactériens
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
WO2011044506A3 (fr) Composés sulfonés et leurs procédés de fabrication et d'utilisation
IN2014DN09805A (fr)
WO2012024583A3 (fr) Composés oxystérol
WO2008097924A3 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques
WO2010030704A3 (fr) Analogues d’aminoglycosides antibactériens
WO2007135527A3 (fr) Composés de benzimidazolyle
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX2011012122A (es) Derivados de tiofeno.
WO2012154679A8 (fr) Composés de sulfonamide pyrazole tricycliques et leurs procédés de fabrication et d'utilisation
WO2010132757A3 (fr) Analogues d'aminoglycoside antibactériens
WO2010037059A3 (fr) Antagonistes hétéroaryliques des récepteurs de prostaglandine d<sb>2</sb>
IN2014DN09804A (fr)
WO2010132765A3 (fr) Analogues d'aminoglycoside antibactériens
WO2012048129A3 (fr) Inhibiteurs de kinase de type polo
WO2009108720A3 (fr) Antagonistes des récepteurs d2 de la prostaglandine
WO2012054110A3 (fr) Composés et procédés permettant d'inhiber le transport du phosphate
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
WO2009064460A3 (fr) Systèmes de délivrance aux voies gastro-intestinales
WO2008000483A3 (fr) Composés organiques
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11752693

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11752693

Country of ref document: EP

Kind code of ref document: A2